Federal Circuit Affirms Obviousness of Rifaximin Polymorph Patents and Denial of Motion to Modify Judgment After Post-Trial Patented Indication Carve Out - Mintz
Federal Circuit affirmed obviousness of Rifaximin polymorph patents and denied motion to modify judgment after post-trial patented indication carve out, potentially impacting generic entry for Rifaximin.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 28, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Branded drug makers (e.g., Salix Pharmaceuticals), generic/ANDA manufacturers, API & contract manufacturers involved in Rifaximin production. should confirm how it applies to their specific situation before acting. There is a time constraint attached: No immediate deadline, but monitor for potential generic entry and adjust business plans accordingly.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Court upheld that Rifaximin polymorph patents are obvious, removing a barrier for generic competition, but denied modification of judgment regarding indication carve out.
Who it affects
Branded drug makers (e.g., Salix Pharmaceuticals), generic/ANDA manufacturers, API & contract manufacturers involved in Rifaximin production.
What you must do
Review patent status and assess impact on ANDA filings or product launches for Rifaximin; consult legal counsel for specific product strategies.
Deadline
No immediate deadline, but monitor for potential generic entry and adjust business plans accordingly.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Court of Appeals Affirms Judgment that Struck Down Rule Mandating Price Disclosure in Pharmaceutical Ads - Holland & Knight
- Virginia Prepares to Accept Applications for a Single Medical Cannabis License for Health Service Area 1, Which Includes the Shenandoah Valley - Foley Hoag
- Glenmark suffers recall, warning letter after subpar investigation into tablet manufacturing glitch - Fierce Pharma
- February 17, 2026: Pennsylvania compounding pharmacy earns another FDA warning letter - Partnership for Safe Medicines
- Governor signs bill requiring informed consent for nursing home patients for prescription of antipsychotic drugs - Oklahoma State Senate (.gov)